Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | RGS4 | P49798 | 1/20 | 0.31 |
| ▸ | RGS8 | P57771 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | INMT | O95050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2105444 | 0.62 | TDP1 (0.30) | — | |
| SCHEMBL21931153 | 0.62 | ALDH1A1 (0.32) | KDM4E | |
| SCHEMBL21929550 | 0.62 | PDE7A (0.35) | — | |
| SCHEMBL10047085 | 0.59 | CRBN (0.54) | — | |
| SCHEMBL19846462 | 0.59 | TDP1 (0.33) | KDM4E | |
| SCHEMBL16603959 | 0.59 | RGS4 (0.32) | RGS4RGS8 | |
| SCHEMBL23346675 | 0.58 | CCR9 (0.33) | — | |
| SCHEMBL23346927 | 0.58 | — | — | |
| SCHEMBL16118582 | 0.57 | — | — | |
| SCHEMBL9322051 | 0.57 | CA12 (0.33) | CA12CA1CA9RGS4RGS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| US-9593107-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593107-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150376180-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | CA12 3044/4885CA1 4023/4885CA9 4187/4885 |
| US-20150376180-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | RECQL, QDPR, NDUFC2 | CA12 4585/4885CA1 4251/4885CA9 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.